- Services
- Therapeutic Areas
- Model Systems
- In Vitro
- In Vivo
- Technologies
- Service Type
- About Us
- Our Science
- Start Your Study Now
Castrate-resistant prostate cancer (CRPC); Recurrent chromosomal abnormalities included losses on chromosomes10q (includingPTEN and MXI1), 12p, 13q (including Rb1), 17p (including TP53), 18q, 3Mb deletion between ERG and TMPRSS2 on Ch21, 6q, and 9q. Gains included the q-arm of X,which was confirmed by PCR for ARTMPRSS-ETS fusion.
| Summary | |
|---|---|
| Cancer Type | prostate-cancer |
| Subtype | CRPC |
| Grade | NA |
| Stage | M(b1) |
| Ethnicity | Western |
| Gender | M |
| Age | 67 |
| Pathology Diagnosis | Castrate-resistant prostate cancer (CRPC); Recurrent chromosomal abnormalities included losses on chromosomes10q (includingPTEN and MXI1), 12p, 13q (including Rb1), 17p (including TP53), 18q, 3Mb deletion between ERG and TMPRSS2 on Ch21, 6q, and 9q. Gains included the q-arm of X,which was confirmed by PCR for ARTMPRSS-ETS fusion. |
| Biopsy Site | primary |
| Treatment History | HT, CT |
| Pathology QC | Prostate cancer(PR6512-H149/5+C 10/1), poorly differentiated prostate adenocarcinoma; P504(+/-), 34bE12(nearly 1%: 1+), CK8(2+), PSA(<1%: 1+), Nkx3.1(2~3+), AR(3+), p63(2+) |
| Special Features | CRPC, model expansion is needed prio to study. |
| Mouse Strain | Rag2-/-?C-/-, NSG |
| TMA | NA |
| Viral Status in PDX | NA |
| Available In | CB_UK |
| RNA Seq | P3 |
| Exome Seq | P3 |
